VALBIOTIS
7.6.2019 07:37:06 CEST | Business Wire | Press release
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases, today announced that new preclinical results of TOTUM-63 obtained independently by Leiden University (Netherlands) will be presented at the 2019 scientific sessions of the American Diabetes Association, being held from June 7 to 11 in San Francisco, California. In a murine model of prediabetes, TOTUM-63 reduced inflammation in visceral adipose tissue, one of the pathophysiological mechanisms of metabolic diseases, especially type 2 diabetes. Moreover, this study also confirmed the efficacy of TOTUM-63 on sugar and lipid metabolism in this preclinical model.
"This study from Leiden University is important from a scientific standpoint: it demonstrates a new effect of TOTUM-63, the active substance of lead product candidate VALEDIA ® , on visceral adipose tissue inflammation that enriches the multi-target mode of action of TOTUM-63. On the clinical side, as previously announced, we expect to report the results of the international Phase IIA clinical study of VALEDIA ® before July 31 st ," comments Sébastien PELTIER, CEO of VALBIOTIS.
Anti-inflammatory action on visceral adipose tissue
"Obesity, in both humans and mice, leads to an increase and an activation of macrophages in visceral adipose tissue. These immune cells are involved in maintaining a silent metabolic inflammation, thus reducing the body's ability to use insulin. By reducing this inflammation and increasing insulin sensitivity in adipose tissue, TOTUM-63, the active substance of VALEDIA ® , would contribute to the reduction of the release of lipids into the bloodstream," specifies Dr. Bruno GUIGAS, researcher at Leiden University (Netherlands), the lead investigator of the study.
The discovery of this new effect further enriches the multi-target mode of action of TOTUM-63, which was presented at the European Association for the Study of Diabetes (EASD) congress in 2018. This mode of action would already combine the preservation of the pancreas, the improvement of insulin signaling in the muscle and the adipose tissue, the reduction in hepatic steatosis and an improved composition of the intestinal microbiota.
About TOTUM-63, the active substance of VALEDIA ®
Prediabetes is a growing public health issue worldwide that has been acknowledged by international organizations. Without appropriate management, 70% to 90% of prediabetic subjects will develop type 2 diabetes.
VALEDIA® intend to be the first natural and clinically proven solution specifically designed for prediabetics. VALEDIA® contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of type 2 diabetes.
The launch of VALEDIA® is planned for 2021, with a health claim for reducing the risk of type 2 diabetes.
TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the first international Phase IIA study are expected before 31 July 2019.
ABOUT VALBIOTIS
VALBIOTIS is a French Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).
VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS:
http://valbiotis.com/
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
Disclaimer
This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 5 April 2017 (application number I.17-012), as well as in the 2017 annual financial report, filed with AMF on 3 April 2018. This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005627/en/
Contact:
VALBIOTIS CORPORATE COMMUNICATION Carole Rocher / Marc Delaunay +33 5 46 28 62 58 medias@valbiotis.com
FINANCIAL COMMUNICATION ACTIFIN Stéphane Ruiz +33 1 56 88 11 14 sruiz@actifin.fr
MEDIA RELATIONS MADIS PHILEO Guillaume De Chamisso +33 6 85 91 32 56 guillaume.dechamisso@madisphileo.com
UNITED STATES SOLEBURY TROUT Rebecca John / Patrick Till +1 646 378 2935 rjohn@troutgroup.com ptill@troutgroup.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™11.2.2026 07:00:00 CET | Press release
Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2 Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma’s proprieta
Suzano Reports Record Sales and Continued Improvements in Operational Efficiency in 202511.2.2026 00:44:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its results for both the final quarter (4Q25) and the full year (2025), reporting record annual sales volumes and net revenue. The company also reported an improvement in its cash cost of pulp production, reflecting the drive for improved operational efficiency. Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. This performance was driven primarily by the strong operational contribution of the Ribas do Rio Pardo pulp mill, which began production in July 2024, and the company’s paper mills in the United States. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. The company’s consistent focus on efficiency and cost discipline also contributed to a meaningful reduction in the cash cost of pulp production. Excluding downtime, the annual cash cost was R$817 per tonne, reaching its lowest annual level since 2021. Operational efficiency also helped Suzano deliver operating cas
Eclipse Signs Partnership Agreement With BNP Paribas to Power the Next Stage of Growth11.2.2026 00:05:00 CET | Press release
The agreement includes a strategic equity investment in Eclipse by BNP Paribas Eclipse, a leading battery storage, development, and energy trading company, and BNP Paribas, one of the largest banks in the Eurozone, today announced a strategic partnership to accelerate the deployment of Battery Energy Storage Systems (BESS) and strengthen Europe's energy resilience. This partnership includes a strategic equity investment in Eclipse by BNP Paribas. Through its proprietary algo trading software, Flowstream, Eclipse optimizes battery energy storage assets in real-time for its own and third-party assets. As an integrated BESS player, Eclipse develops, owns, and operates industrial-scale energy assets. The company currently has a pipeline of 16 projects in France and Belgium, representing a total capacity of 850 MW. The partnership with BNP Paribas provides asset owners with tailored financing solutions for BESS projects, as well as hedging instruments to manage merchant risk and reduce asse
World Governments Summit 2027 Date Announced, Following Largest-Ever Global Participation10.2.2026 22:06:00 CET | Press release
Largest edition in the summit’s history convened 6,250+ global leaders, policymakers, and experts from 150+ countriesWorld leaders, including presidents from Switzerland, Sierra Leone, and beyond, lead strategic dialogues Under the leadership of UAE President His Highness Sheikh Mohamed bin Zayed Al Nahyan and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the World Governments Summit concluded in Dubai with its largest-ever participation, featuring more than 6,250 attendees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210283291/en/ World Governments Summit 2026 concludes in Dubai with record participation, bringing together more than 6,250 global leaders from over 150 countries to advance dialogue on governance, innovation, and sustainable development (Photo: AETOSWire) A Global Platform Convening Global Leaders Held in Dubai from 3 to 5 February, t
Palantir and Airbus Extend Strategic Collaboration10.2.2026 22:01:00 CET | Press release
Palantir Technologies (NASDAQ:PLTR) is proud to announce the extension of its collaboration with Airbus through a multi-year agreement, confirming a relationship that has driven innovation across the aerospace industry for over a decade. Under this renewed contract, Airbus will continue to rely on Palantir for Skywise, its civil aviation open data platform. The Skywise platform enhances aircraft and equipment designs and enables greater efficiency, safety and sustainability in the production of civil aircraft across the Airbus industrial footprint. It also improves the performance of airlines’ operations by combining in-flight engineering and operational data in an analytic rich environment enabling airlines to address their main challenges. This renewed commitment comes at a pivotal time, as the aerospace sector faces demands for innovation, agility, and competitiveness. With this renewed collaboration, Palantir will provide Airbus and its customers with continued access to cutting-ed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom